PPARA and metabolic dysfunction-associated steatotic liver disease: The ameliorating effect of AMY against NAFLD appeared to simulate fenofibrate, a known lipid-lowering drug used as a control, which is in fact a PPAR-α agonist that functions through the activation of lipoprotein lipase, and by inducing changes in the transcription of genes encoding enzymes involved in lipid and lipoprotein metabolism (39).